A novel serum and tissue immunoglycomic biomarker panel to distinguish progressive Prostate Cancer

Project: Research project

Project Details

Description

Aim 1: Determine the sensitivity and specificity of tissue/serum sMIC in predicting PSA recurrence (BCR) and/or variant (NE-like) progressive PCa. These assays will be done by immunohistochemistry for tissues and ELISA for serum.
Aim 2: Identify and evaluate clinically and biologically significant N-glycan panels and autoantibodies in tissue and serum associated with BCR and/or NE-like PCa. We will determine N-glycan panels in the same tissue/serum cohorts as in Aim 1 using MALDI imaging mass spectrometry.
Aim 3: Validate prognostic capacity of the identified panel of serum biomarkers. We will perform this validation study in three independent cohorts of PCa patient samples with annotated prognostic information.
StatusActive
Effective start/end date9/30/179/29/20

Funding

  • U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0642)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.